19 results
Thumbnail

D1.227 - Nanobody-based anti-FcεRI antibodies for therapeutic targeting of the IgE-FcεRI complex

Thumbnail

D1.228 - Mitochondrial Epigenetic Programming: A Unifying Mechanism Linking Environmental Stress, Epithelial Barrier Dysfunction, and Allergy

Thumbnail

D1.229 - Real-life observational study on allergen-specific Immunotherapy with double-polymerized allergoids (Modigoid Cup a1) in patients allergic to Cupressus Arizonica pollen

Thumbnail

D1.218 - Effects of butyrylated high amylose maize starch (HAMSB) as an adjuvant for oral immunotherapy

Thumbnail

D1.219 - Efficacy and Safety of 300 IR Liquid Sublingual Immunotherapy in Allergic Asthma: A Systematic Review and Meta-analysis of Randomised Controlled Trials

Thumbnail

D1.221 - Identification of IgE epitopes of major ragweed pollen allergens (Amb a 1 and Amb a 11)

Thumbnail

D1.222 - Production of Bet v 1-specific IgG antibodies in mice immunized with the recombinant vaccine ABP-Vax

Thumbnail

D1.223 - TNFR2 regulates early PD-L1/PD-L2 induction and Th1-associated cytokine responses during the early events of Allergen-Specific Immunotherapy (AIT) in a preclinical model

Thumbnail

D1.224 - Rational Design of a T-Cell Epitope-Based Chimeric Allergen from Dermatophagoides pteronyssinus Toward Precision Immunotherapy

Thumbnail

D1.225 - Long-term adherence to seasonal allergen immunotherapy: a 3-year (22/23-24/25) retrospective study on 174 patients

Thumbnail

D1.226 - Allergen Immunotherapy Preferences by Patient in Some Arabic countries: The CHOICE-Middle East Study

Thumbnail

D1.230 - Efficacy and Safety of Hymenoptera Venom Immunotherapy in a Patient with Systemic Mastocytosis

Thumbnail

D2.114 - Occupational asthma and rhinitis in a worker in the single-use food packaging industry: challenges of multi-agent exposure

Thumbnail

D2.115 - Occupational asthma and rhinitis to isocyanates in industrial settings

Thumbnail

D2.108 - Type 2 Inflammation Biomarkers in Patients with Chronic Rhinosinusitis with Nasal Polyps Under Treatment with Biologic Agents

Thumbnail

D2.110 - Real-world evaluation of tezepelumab in patients with severe asthma and chronic rhinosinusitis in France: preliminary results from the ROSE retrospective study

Thumbnail

D2.113 - Comparison of Non-Asthmatic Allergic Rhinitis Patients with Normal and Low FEF25–75 Levels

Thumbnail

D2.120 - Missing the Red Flags? Identification of High-Risk Paediatric Asthma Admissions Following the 2024 BTS/NICE/SIGN Update

Thumbnail

D2.121 - Seroprotection to influenza virus in vaccinated patients with bronchial asthma on biological treatment